⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 10, 2020Expert Opinion on Emerging DrugsOpen Access

Bruton’s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis

Edgar Carnero Contentti Jorge Correale

View Full Paper

Ask AI

Bookmark

Share

Abstract

Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) leading to demyelination and neurodegeneration. Although its etiology is not fully understood yet, gene...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Contentti et al. (2020) studied this question.

synapsesocial.com/papers/6a86642f004d97ec463a6fe2 https://doi.org/10.1080/14728214.2020.1822817

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Multiple SclerosisOriginal Research · 2018 · 2,479 citations
2Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple SclerosisIn Vitro Study · 2018 · 509 citations
3Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)Original Research · 2011 · 651 citations
4Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaOriginal Research · 2013 · 2,262 citations
5Inhibition of BTK protects lungs from trauma-hemorrhagic shock-induced injury in ratsOriginal Research · 2017 · 20 citations

More related papers

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice2012
Dual Functions of Bruton’s Tyrosine Kinase and Tec Kinase during Fcγ Receptor-Induced Signaling and Phagocytosis2008
Involvement of Bruton's Tyrosine Kinase in FcεRI-dependent Mast Cell Degranulation and Cytokine Production1998

More from Expert Opinion on Emerging Drugs

Emerging drugs for diabetic macular edema: an updateThu,
Emerging therapies for pericarditis: from anti-IL-1 agents to novel therapeutic optionsTue,